These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21122492)

  • 1. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease.
    Uslu N; Usta Y; Saltik-Temizel IN; Demir H; Gürakan F; Ozen H; Yüce A
    J Crohns Colitis; 2010 Feb; 4(1):106-9. PubMed ID: 21122492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
    Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
    Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab.
    Rebelo A; Leite S; Cotter J
    BioDrugs; 2010 Dec; 24 Suppl 1():37-9. PubMed ID: 21175236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation].
    Jung BY; Lee SH; Chung SK; Lee CK; Lee TH; Chung IK; Kim SJ; Cho HD
    Korean J Gastroenterol; 2012 Jun; 59(6):437-40. PubMed ID: 22735878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS; Markowitz J; Wyllie R
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
    Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
    Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ
    Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
    Tang DH; Armstrong EP; Lee JK
    Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.